Condition
Refractory Diffuse Intrinsic Pontine Glioma
Total Trials
4
Recruiting
1
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Active Not Recruiting2
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05278208Phase 1Recruiting
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT02359565Phase 1Active Not Recruiting
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT03598244Phase 1Active Not Recruiting
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
NCT03387020Phase 1Completed
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Showing all 4 trials